May 01 2025
A new study from researchers at the University of Sydney highlights the potential of inhalable cannabidiol (CBD) powder using methyl-β-cyclodextrin (mbCD) as a solubilizing agent to improve drug delivery. The research, published in AAPS PharmSciTech, sought to overcome one of the primary challenges in pulmonary CBD delivery—its low water solubility. Scientists tested multiple solubilizers, including …
Apr 30 2025
A new study published in the journal Cannabis and Cannabinoid Research and indexed by the U.S. National Library of Medicine finds that medical cannabis may provide comparable relief to opioids for chronic noncancer pain, while removing the possibility of overdosing. Researchers from McMaster University and the University of British Columbia used data from 90 randomized …
Apr 30 2025
A new clinical trial finds that psilocybin could offer a safe and effective way to ease depression, anxiety, and motor symptoms in people with Parkinson’s disease. A pilot study conducted by researchers at the University of California is the first to examine psilocybin’s effects in individuals with a neurodegenerative disorder. Published in the journal Neuropsychopharmacology, …
Apr 29 2025
According to a new study that used an animal model, cannabidiol (CBD) may help regulate sleep disorders caused by general anesthesia. For the study, researchers implanted cortical EEG electrodes in 24 male rats and divided them into four groups: control, propofol, CBD treatment, and diazepam treatment. Following anesthesia with propofol, the rats received daily treatment …
Apr 28 2025
A new study published in the journal Epilepsy & Behavior found that cannabidiol (CBD) may be a highly effective adjunct treatment for patients with drug-resistant epilepsy (DRE), helping to significantly lower seizure frequency across a variety of epilepsy types. Researchers from Tulane University School of Medicine, the Donald and Barbara Zucker School of Medicine, the …
Apr 26 2025
Published by The International Journal of Psychiatry in Medicine, a new study found that psilocybin may quickly reduce depression and anxiety symptoms in cancer patients. The research was conducted by scientists from LUXMED Group, the John Paul II Catholic University of Lublin, and the Medical University of Gdansk in Poland, the International European University in …
Apr 26 2025
Researchers in Spain have developed a novel CBD-based nanoparticle system that could improve the management of metabolic diseases, according to a study published in the Journal of Biomedical Materials Research Part A. The study, conducted by researchers from Universidad de Sevilla, University of Cádiz, Universitario Virgen del Rocío, and Universidad de Cantabria, focused on creating …
Apr 24 2025
A new peer-reviewed study published in the journal Variance found no statistically significant connection between marijuana legalization and increased vehicle accident fatalities, insurance claim frequency, or average claim cost. The research was conducted by the University of Maryland Center for Environmental Science and analyzed data from both Canada and the United States using a variety …
Apr 24 2025
In a new study published in the journal Expert Review of Neurotherapeutics, “cannabis-based medicinal products were associated with improvements in PTSD symptoms, anxiety, sleep, and health-related quality of life” over an 18-month period. The study followed 269 PTSD patients who were prescribed cannabis-based medicinal products (CBMPs) for at least 18 months. Conducted by researchers from …
Apr 24 2025
According to a study conducted by researchers from eight universities, cannabinoids may be effective in managing core symptoms of Tourette Syndrome. A new systematic review and meta-analysis has found that cannabis-based medications may significantly reduce the severity of tics and premonitory urges in individuals with Tourette Syndrome. The study was conducted by researchers from eight …
